+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates



In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates



Journal of Antimicrobial ChemoTherapy 50(1): 140-142




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010811668

Download citation: RISBibTeXText

PMID: 12096023

DOI: 10.1093/jac/dkf081


Related references

In vitro activity of a novel des-fluoro quinolone BMS-284756 against rapidly growing mycobacteria and Nocardia isolates. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 175, 2001

Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients. Diagnostic Microbiology and Infectious Disease 44(2): 187-194, 2002

Synergistic activity of the novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species. International Journal of Antimicrobial Agents 20(1): 57-60, 2002

Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 49(2): 283-287, 2002

In vitro activity of the novel des-F(6) quinolone BMS-284756 against genetically characterized clinical streptococcal isolates, including isolates with reduced quinolone susceptibility. Journal of Antimicrobial ChemoTherapy 49(4): 698-701, 2002

In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest. Journal of Clinical Microbiology 54(6): 1586-1592, 2017

Antimicrobial activity of a novel des-fluoro quinolone, garenoxacin , compared to other quinolones, against clinical isolates from cancer patients. Diagnostic Microbiology & Infectious Disease 44(2): 187-194, 2002

In vitro activity of the novel des- fluoro quinolone, BMS-284756, against anaerobic bacteria. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 173, 2000

The in vitro activity of the novel des- fluoro quinolone BMS-284756 against fastidious bacterial species. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 174, 2000

In vitro activity of linezolid against isolates of rapidly growing mycobacteria. Abstracts of the General Meeting of the American Society for Microbiology 100: 654, 2000

Susceptibility of rapidly growing mycobacteria and Nocardia isolates from cats and dogs to pradofloxacin. Veterinary Microbiology 153(3-4): 240-245, 2012

The in vitro activity of the novel des- fluoro quinolone BMS-284756 against anaerobes, mycoplasma, ureaplasma, chlamydia, and mycobacterium spp. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 174, 2000

In vitro activity of novel Des-F quinolone, BMS-284756, against 590 anaerobic clinical isolates. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 173, 2000

Pharmacodynamic evaluation of garenoxacin, a des-fluoro quinolone, against quinolone-resistant Streptococcus pneumoniae in an in vitro model simulating serum concentration. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 17, 2003

Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance. Antimicrobial Agents and ChemoTherapy 46(4): 1119-1121, 2002